Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer

Junyl Hwang, Sang Hee Cho, Jeong Shim Hyun, Se Ryeon Lee, Sook Ahn Jae, Duk Hwan Yang, Yeo Kyeoung Kim, Je Jung Lee, Hyeoung Joon Kim, Ik Joo Chung

Research output: Contribution to journalArticle

10 Citations (Scopus)


This phase II study evaluated the efficacy and safety of combination chemotherapy with paclitaxel, cisplatin, and 5-fluorouracil (5-FU) in advanced gastric cancer. Patients with histologically confirmed gastric adenocarcinoma were eligible for the study. Paclitaxel (175 mg/m2) and cisplatin (75 mg/m2) were given as a 1-hr intravenous infusion on day 1, followed by 5-FU (750 mg/m2) as a 24-hr continuous infusion for 5 days. This cycle was repeated every 3 weeks. Forty-five eligible patients (median age, 56 yr) were treated in this way. Of the 41 patients in whom efficacy was evaluable, an objective response rate (ORR) was seen in 51.2% (95% CI, 0.35-0.67), a complete response in two, and a partial response in 19 patients. The median progression free survival was 6.9 months (95% CI, 5.86-7.94 months), and the median overall survival was 12.7 months (95% CI, 9.9-15.5). The main hematological toxicity was neutropenia and greater than grade 3 neutropenia was observed in twelve patients (54%). Febrile neutropenia developed in three patients (6.8%). The major non-hematological toxicities were asthenia and peripheral neuropathy, but most of patients showed grade 1 or 2. In conclusion, combination chemotherapy with paclitaxel, cisplatin, and 5-FU is a promising regimen, and was well tolerated in patients with advanced gastric cancer.

Original languageEnglish
Pages (from-to)586-591
Number of pages6
JournalJournal of Korean medical science
Issue number4
Publication statusPublished - 2008 Aug 1
Externally publishedYes



  • Cisplatin
  • Fluorouracil
  • Paclitaxel
  • Stomach neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this